568513-U

Discovery^® HS C18 (5 µm) HPLC Columns

L × I.D. 25 cm × 4 mm, HPLC Column

• 同義詞: Discovery RP18 HPLC Column
• 分類程式碼代碼: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

屬性

• product name: Discovery^® HS C18 高效液相色谱柱, 5 μm particle size, L × I.D. 25 cm × 4 mm
• 材料: stainless steel column
• 品質等級: 100
• agency: suitable for USP L1
• 產品線: Discovery^®
• 特點: endcapped
• 製造商／商標名: Discovery^®
• 包裝: 1 ea of
• 標籤範圍: 20% Carbon loading
• 參數: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• 技術: HPLC: suitable; LC/MS: suitable
• 長度 × 內徑: 25 cm × 4 mm
• 表面積: 300 m²/g
• 表面覆盖率: 3.2 μmol/m²
• 雜質: <10 ppm metals
• 基質: silica gel, high purity, spherical particle platform; fully porous particle
• 基質活性組: C18 (octadecyl) phase
• 粒徑: 5 μm
• 孔徑: 120 Å
• 工作pH值範圍: 2-8
• 應用: food and beverages
• 分離技術: reversed phase

描述

應用

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This research developed a robust RP-HPLC method for the quantitative analysis of molnupiravir, a COVID-19 therapeutic, utilizing nanoformulations. The study highlights the method′s stability and effectiveness in permeability studies, demonstrating its potential in pharmaceutical analysis (Reçber et al., 2022).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: The study developed and validated an HPLC-UV method for analyzing terizidone in plasma, essential for pharmacokinetic studies in patients with drug-resistant tuberculosis. The method′s reliability supports its use in clinical and pharmacological research (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: This research focuses on optimizing a liquid chromatography method to quantify doxorubicin in plasma and urine. It is crucial for pharmacokinetic, biomedical, and drug monitoring studies, ensuring accurate and precise therapeutic monitoring (Maliszewska et al., 2018).


• Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV.: This study introduces a universal HPLC-UV method for determining efavirenz in various biological matrices, including transport studies, rat placenta perfusion, and lysate. It is significant for pharmacokinetic and drug distribution research (Zelena et al., 2017).

特點和優勢

• 稳定性好、低流失，适用于 LC-MS 分析
• 提供有适用于分析型到制备型的各种规格
• 稳定性好，以确保柱与柱和批与批之间之间优良的重现性
• 更强的疏水性能够更好地分离难分析化合物

   

推薦產品

探索最适于 HPLC 或 LC-MS 分析的 LiChropur 试剂

法律資訊

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany